US Diabetes Patients Face Delays as Insurers Tighten Ozempic Coverage
Novo Nordisk confirmed in a recent email that it is seeing tighter
health plan management of GLP-1 drugs including Ozempic and is working
to minimize disruption for type 2 diabetes patients. The trend has
contributed to a recent dip in U.S. prescriptions, an executive at the
Danish drugmaker said at an investor conference last month.
Out of 24 diabetes patients contacted by Reuters on Reddit, 13 reported
recent problems getting their health plans to cover Ozempic or Mounjaro
или
Thousands of people in Michigan who use popular weight loss drugs will
soon lose their coverage for it.
Blue Cross Blue Shield of Michigan, the state's largest health insurer,
announced it would end its funding for GLP-1 obesity drugs starting from
January 1 next year.
This move will affect close to 10,000 people on these medications,
according to Bloomberg.
